ORBITAL THERAPEUTICS
Live / Applied — First extension granted (statement of use) (as of 16 Sept 2025)
What this means for you
Not registered yet, but its 12 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98597164
- Mark type
- Design + words
- Filed
- 12 Jun 2024
- Published for opposition
- 11 Mar 2025
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of diseases and disorders related to the immune system, autoimmune diseases and disorders, cancer, oncology indications, or hematologic disorders; Pharmaceutical preparations in the nature of protein-based therapeutics for the treatment of diseases and disorders related to the immune system, autoimmune diseases and disorders, cancer, oncology indications, or hematologic disorders; Therapeutic and preventative vaccines; Medical, biological and pharmaceutical preparations containing polypeptide encoding nucleic acids for the prevention and treatment of infectious diseases and disorders, immunologic disorders, oncology indications, or hematologic disorders; RNA-based therapeutics for the treatment and prevention of infectious diseases and disorders, immunologic disorders, oncology indications, or hematologic disorders; Therapeutic agents for the treatment of diseases and disorders related to the immune system, autoimmune diseases and disorders, cancer, oncology indications, or hematologic disorders
- Class 042 — Scientific and technological services: Research and development in the biotechnology field; Consulting services in the fields of biotechnology and genetic science; Development of new technology for others in the fields of genomics and biotechnology; Providing laboratory research services in the field of gene expression or RNA-based therapeutics; Testing, inspection, research, or development of chemical and biotechnology preparations; Scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars and therapeutics; Design, engineering, research, development and testing services in the field of protein-encoding nucleic acids and polypeptide-encoding nucleic acids; Providing information on the subject of scientific and medical research in the fields of biotechnology, biologics, biosimilars, pharmaceuticals, vaccines, and therapeutics related to genetic science, genomics, gene expression, protein-encoding nucleic acids or polypeptide-encoding nucleic acids
Owner
- Orbital Therapeutics, Inc., Cambridge, MA, US
- Orbital Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 17 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Sept 2025 — SOU EXTENSION 1 GRANTED
- 16 Sept 2025 — SOU EXTENSION 1 FILED
- 16 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 06 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Mar 2025 — PUBLISHED FOR OPPOSITION
- 05 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Feb 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 13 Feb 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 18 Dec 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 18 Dec 2024 — NON-FINAL ACTION E-MAILED
- 18 Dec 2024 — NON-FINAL ACTION WRITTEN